Swedish Orphan Biovitrum will present new evidence at the upcoming 11th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), in Madrid, Spain, 7-9 February 2018.
These data mark the company´s commitment to elevate haemophilia management and expand the available clinical evidence for Elocta and Alprolix, demonstrating the need to rethink the current concept of protection, and advance the standard of haemophilia care for people with haemophilia A and B, according to the company.
“Bleeding control and prevention remain the cornerstone of haemophilia care, however new findings advocate for a more holistic view on protection that can never compromise on safety. This is built on prevention and treatment of bleeds, joint health, freedom of pain, as well as patient´s preferences, physical activity and overall quality of life”, said Philip Wood, Head of Haemophilia at Sobi. “This may encourage the haemophilia community to re-think the current definition of protection and evolve the standard of care”.
In line with this, one of the posters presented by Sobi includes the first real world comparison of prophylactic treatment in patients with haemophilia A,before and after switching from conventional rFVIII therapy, to Elocta (rFVIIIFc). The data, gathered from the UK National Haemophilia Database, demonstrates a significant reduction of injection frequency and clotting factor consumption and provides further evidence that extended half-life rFVIII products can reduce treatment burden.
Sobi will also present the results of pharmacokinetic simulations for different prophylactic treatments and dosing regimens for haemophilia A in Germany, and the economic impact thereof. The simulation suggests that by using rFVIIIFc instead of conventional rFVIII therapy it is possible to achieve better bleed protection and extend the dosing interval, lower factor consumption and reduce healthcare costs.
“Protection for people with haemophilia should always be made a priority without compromising on safety”, said MD, PhD, Armin Reininger, Head of Medical and Scientific Affairs, at Sobi.